Phase 3, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus

View Statistics Email Alert RSS Feed

Grant Data
Project Title
Phase 3, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus
Principal Investigator
Dr Ho, James Chung Man   (Principal Investigator (PI))
Co-Investigator(s)
Dr Lam Chi Leung David   (Co-Investigator)
Dr Wong King Yan Matthew   (Co-Investigator)
Dr Lam Chung Mei Jamie   (Co-Investigator)
Duration
24
Start Date
2010-04-07
Amount
51616
Conference Title
Phase 3, randomized, open-label study of the efficacy and safety of PF-02341066 versus standard of care chemotherapy (pemetrexed or docetaxel) in patients with advanced nonsmall cell lung cancer (NSCLC) harbouring a translocation or inversion event involving the anaplastic lymphoma kinase (ALK) gene locus
Presentation Title
Keywords
anaplastic lymphoma kinase, non-small cell lung cancer
Discipline
Cancer,Respiration
HKU Project Code
N/A
Grant Type
Pharmaceutical Industry - General Award
Funding Year
2010
Status
On-going